Catalyst Event
Jiangsu Hengrui Pharmaceuticals Co Ltd (1276) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
4/28/2026, 12:00:00 AM
Subsidiary clinical trial approval for SHR-2173 (myasthenia gravis) on April 28, 2026; low importance reflects expected >1% price impact. scheduled
Korean Translation
2026년 4월 28일 자회사의 SHR-2173 주사제(중증 근무력증) NMPA 임상시험 승인 발표 예정. 1% 이상의 주가 영향이 예상됨
Related Recent Events
WuXi Biologics (Cayman) Inc (2269) · Other
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
12/18/2026, 12:00:00 AM
WuXi AppTec Co Ltd (2359) · Other
Ex-dividend date on May 13, 2026, for the 2025 final cash dividend of RMB 1.57927 per share (RMB 15.7927 per 10 shares); low impact estimated as price typically adjusts by the dividend amount, scheduled.
5/13/2026, 12:00:00 AM
Gilead Sciences Inc (GILD) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-07. This event is estimated to have a high price impact as quarterly results often drive significant market volatility scheduled.
5/7/2026, 12:00:00 AM
Kenvue Inc (KVUE) · Earnings Release
Kenvue will announce its first quarter 2026 financial results before the market opens on May 7, 2026. Based on historical earnings volatility, a 5% price impact is expected.
5/7/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer is scheduled to release its Q1 2026 earnings results before the market opens on May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM
Vertex Pharmaceuticals Inc (VRTX) · Earnings Release
Vertex Pharmaceuticals is scheduled to announce its first-quarter 2026 financial results after the market closes on May 4, 2026. This earnings release is estimated to have a >=5% price impact, scheduled
5/4/2026, 12:00:00 AM